The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Progressive Multifocal Leukoencephalopathy and Natalizumab — Unforeseen Consequences
Abstract
In this issue of the Journal, there are reports describing in detail three patients in whom progressive multifocal leukoencephalopathy (PML) developed during treatment with natalizumab, a humanized monoclonal antibody against α4 integrins.13 These patients were among 3000 who had participated in clinical trials of natalizumab for the treatment of multiple sclerosis or Crohn's disease. PML is a deadly opportunistic infection of the central nervous system (CNS) for which there is no specific treatment. It is caused by reactivation of a clinically latent JC polyomavirus infection. This virus infects and destroys oligodendrocytes, leading to multifocal areas of demyelination and . . .
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Kleinschmidt-DeMasters, B. K., & Tyler, K. L. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051782 · Cited by 1,072
Progressive Multifocal Leukoencephalopathy after Natalizumab Therapy for Crohn's Disease
Van Assche, G., Van Ranst, M., Sciot, R., Dubois, B., Vermeire, S., Noman, M., Verbeeck, J., Geboes, K., Robberecht, W., & Rutgeerts, P. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051586 · Cited by 1,060
Progressive Multifocal Leukoencephalopathy in a Patient Treated with Natalizumab
Langer-Gould, A., Atlas, S. W., Green, A. J., Bollen, A. W., & Pelletier, D. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051847 · Cited by 1,034
Knowles, W. A., Pipkin, P., Andrews, N., Vyse, A., Minor, P., Brown, D. W. G., & Miller, E. (2003) · Journal of Medical Virology · doi:10.1002/jmv.10450 · Cited by 586
Hall, C. D., Dafni, U., Simpson, D., Clifford, D., Wetherill, P. E., Cohen, B., McArthur, J., Hollander, H., Yainnoutsos, C., Major, E., et al. (1998) · New England Journal of Medicine · doi:10.1056/nejm199805073381903 · Cited by 346
The effect of anti-α4 integrin antibody on brain lesion activity in MS
Tubridy, N., Behan, P. O., Capildeo, R., Chaudhuri, A., Forbes, R., Hawkins, C. P., Hughes, R. A. C., Palace, J., Sharrack, B., Swingler, R., et al. (1999) · Neurology · doi:10.1212/wnl.53.3.466 · Cited by 307
Du Pasquier, R. A. (2004) · Brain · doi:10.1093/brain/awh215 · Cited by 208
Natalizumab: α4-integrin antagonist selective adhesion molecule inhibitors for MS
Rudick, R. A., & Sandrock, A. (2004) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.4.4.571 · Cited by 170
Groothuis, D. R., Benalcazar, H., Allen, C. V., Wise, R. M., Dills, C. V., Dobrescu, C., Rothholtz, V. S., & Levy, R. M. (2000) · Brain Research · doi:10.1016/s0006-8993(99)02089-2 · Cited by 83
Cited by
Neutrophils and immunity: challenges and opportunities
Nathan, C. (2006) · Nature reviews. Immunology · doi:10.1038/nri1785 · Cited by 2,971
Natalizumab plus Interferon Beta-1a for Relapsing Multiple Sclerosis
Rudick, R. A., Stuart, W. H., Calabresi, P. A., Confavreux, C., Galetta, S. L., Radue, E.-W., Lublin, F. D., Weinstock-Guttman, B., Wynn, D. R., Lynn, F., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa044396 · Cited by 1,344
Mechanism of Action of Oral Fingolimod (FTY720) in Multiple Sclerosis
Chun, J., & Hartung, H.-P. (2010) · Clinical Neuropharmacology · doi:10.1097/wnf.0b013e3181cbf825 · Cited by 796
The ins and outs of T-lymphocyte trafficking to the CNS: anatomical sites and molecular mechanisms
Engelhardt, B., & Ransohoff, R. M. (2005) · Trends in Immunology · doi:10.1016/j.it.2005.07.004 · Cited by 673
Metadata
- Authors
- Berger, J. R., & Koralnik, I. J.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2005-07-28
- Volume
- 353
- Issue
- 4
- Pages
- 414-416
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2088205067
- Cited by
- 271
- References
- 9
- FWCI
- 21.06
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Progressive Multifocal Leukoencephalopathy and Natalizumab — Unforeseen Consequences. https://app.cochat.ai/papers/10.1056/nejme058122
- The paper
- Berger, J. R., & Koralnik, I. J. (2005). Progressive Multifocal Leukoencephalopathy and Natalizumab — Unforeseen Consequences. New England Journal of Medicine. https://doi.org/10.1056/nejme058122
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.